Compare CABA & STRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | STRS |
|---|---|---|
| Founded | 2017 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Homebuilding |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.2M | 168.1M |
| IPO Year | 2019 | N/A |
| Metric | CABA | STRS |
|---|---|---|
| Price | $2.56 | $22.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 7.5K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $31,912,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $15.10 |
| 52 Week High | $3.67 | $26.98 |
| Indicator | CABA | STRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 58.71 |
| Support Level | $2.32 | $21.25 |
| Resistance Level | $2.69 | $24.09 |
| Average True Range (ATR) | 0.21 | 0.80 |
| MACD | 0.03 | 0.26 |
| Stochastic Oscillator | 76.81 | 56.89 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations. Real Estate Operations segment encompasses activities associated with entitlement, development, and sale of real estate. Leasing Operations segment involves leasing of commercial space at retail and mixed-use properties and residences in multi-family properties that company developed. Majority of revenue is from Real Estate Operations.